Literature DB >> 21695771

Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.

Claire Francoz1, Jacques Belghiti, Denis Castaing, Olivier Chazouillères, Jean-Charles Duclos-Vallée, Christophe Duvoux, Jan Lerut, Yves-Patrice Le Treut, Richard Moreau, Ameet Mandot, Georges Pageaux, Didier Samuel, Dominique Thabut, Dominique Valla, François Durand.   

Abstract

Model for End-Stage Liver Disease (MELD) score-based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis. Except for extreme values, high pretransplant MELD scores do not significantly affect posttransplant survival. The MELD score can be used to optimize the allocation of allografts according to a sickest first policy. Most often, patients with small hepatocellular carcinomas (HCCs) and low MELD scores receive extra points, which allow them appropriate access to transplantation comparable to the access of patients with advanced cirrhosis and high MELD scores. In addition to patients with advanced cirrhosis and HCC, patients with a number of relatively uncommon conditions have low MELD scores and a poor prognosis in the short term without transplantation but derive excellent benefits from transplantation. These conditions, which correspond to the so-called MELD score exceptions, justify the allocation of a specific score for appropriate access to transplantation. Here we report the conclusions of the French consensus meeting. The goals of this meeting were (1) to identify which conditions merit MELD score exceptions, (2) to list the criteria needed for defining each of these conditions, and (3) to define a reasonable time interval for organ allocation for each MELD exception in the general context of organ shortages. MELD exceptions were discussed in an attempt to reconcile the concepts of transparency, equity, justice, and utility.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21695771     DOI: 10.1002/lt.22363

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  11 in total

Review 1.  Liver transplantation for metastatic neuroendocrine tumors.

Authors:  Louise Barbier; Cindy Neuzillet; Safi Dokmak; Alain Sauvanet; Philippe Ruszniewski; Jacques Belghiti
Journal:  Hepat Oncol       Date:  2014-12-11

2.  Liver-allocation policies for patients affected by HCC in Europe.

Authors:  Luciano De Carlis; Stefano Di Sandro; Leonardo Centonze; Andrea Lauterio; Vincenzo Buscemi; Riccardo De Carlis; Fabio Ferla; Raffaella Sguinzi; Stefano Okolicsanyi; Luca Belli; Mario Strazzabosco
Journal:  Curr Transplant Rep       Date:  2016-10-07

Review 3.  Model for end-stage liver disease score and MELD exceptions: 15 years later.

Authors:  Sumeet K Asrani; Patrick S Kamath
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

4.  Should we use liver grafts repeatedly refused by other transplant teams?

Authors:  Audrey Winter; Paul Landais; Daniel Azoulay; Mara Disabato; Philippe Compagnon; Corinne Antoine; Christian Jacquelinet; Jean-Pierre Daurès; Cyrille Féray
Journal:  JHEP Rep       Date:  2020-05-04

Review 5.  Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Authors:  Jan Lerut; Samuele Iesari; Maxime Foguenne; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-12

Review 6.  Hepatocellular carcinoma: A comprehensive review.

Authors:  Lisa P Waller; Vrushak Deshpande; Nikolaos Pyrsopoulos
Journal:  World J Hepatol       Date:  2015-11-18

7.  Liver transplantation: fifty years of experience.

Authors:  Alice Tung Wan Song; Vivian Iida Avelino-Silva; Rafael Antonio Arruda Pecora; Vincenzo Pugliese; Luiz Augusto Carneiro D'Albuquerque; Edson Abdala
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

8.  A Donor Quality Index for liver transplantation: development, internal and external validation.

Authors:  Audrey Winter; Cyrille Féray; Etienne Audureau; Daniel Azoulay; Corinne Antoine; Jean-Pierre Daurès; Paul Landais
Journal:  Sci Rep       Date:  2018-06-29       Impact factor: 4.379

9.  Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis.

Authors:  Maëna Le Corvec; Caroline Jezequel; Valérie Monbet; Nadia Fatih; Frédéric Charpentier; Hugues Tariel; Catherine Boussard-Plédel; Bruno Bureau; Olivier Loréal; Olivier Sire; Edouard Bardou-Jacquet
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

Review 10.  Unsolved Questions in Salvage TIPSS: Practical Modalities for Placement, Alternative Therapeutics, and Long-Term Outcomes.

Authors:  Charlotte Bouzbib; Philippe Sultanik; Dominique Thabut; Marika Rudler
Journal:  Can J Gastroenterol Hepatol       Date:  2019-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.